Combined chemotherapy and allogeneic human Vγ9Vδ2 T lymphocyte-immunotherapies efficiently control the development of human epithelial ovarian cancer cells in vivo

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. doi:10.3322/caac.21332.
   PubMed Web of Science ®Google Scholar
• Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL. Ovarian cancer statistics, 2018. CA Cancer J Clin. May 29 2018. doi: 10.3322/caac.21456
   Web of Science ®Google Scholar
• Colombo P-E, Fabbro M, Theillet C, Bibeau F, Rouanet P, Ray-Coquard I. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. Crit Rev Oncol Hematol. 2014;89(2):207–216. doi:10.1016/j.critrevonc.2013.08.017.
   PubMed Web of Science ®Google Scholar
• Ventriglia J, Paciolla I, Pisano C, Cecere SC, Di Napoli M, Tambaro R, Califano D, Losito S, Scognamiglio G, Setola SV, et al. Immunotherapy in ovarian, endometrial and cervical cancer: state of the art and future perspectives. Cancer Treat Rev. 2017;59:109–116. doi:10.1016/j.ctrv.2017.07.008.
   PubMed Web of Science ®Google Scholar
• Mittica G, Capellero S, Genta S, Cagnazzo C, Aglietta M, Sangiolo D, Valabrega G. Adoptive immunotherapy against ovarian cancer. J Ovarian Res. 2016;9(1):30. doi:10.1186/s13048-016-0236-9.
   PubMed Web of Science ®Google Scholar
• Hayday AC. [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol. 2000;18:975–1026. doi:10.1146/annurev.immunol.18.1.975.
   PubMed Web of Science ®Google Scholar
• Chien Y, Meyer C, Bonneville M. γδ T cells: first line of defense and beyond. Annu Rev Immunol. 2014;32:121–155. doi:10.1146/annurev-immunol-032713-120216.
   PubMed Web of Science ®Google Scholar
• Thedrez A, Sabourin C, Gertner J, Devilder M-C, Allain-Maillet S, Fournié -J-J, Scotet E, Bonneville M. Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue? Immunol Rev. 2007;215:123–135. doi:10.1111/j.1600-065X.2006.00468.x.
   PubMed Web of Science ®Google Scholar
• Harly C, Guillaume Y, Nedellec S, Peigné C-M, Mönkkönen H, Mönkkönen J, Li J, Kuball J, Adams EJ, Netzer S, et al. Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset. Blood. 2012;120(11):2269–2279. doi:10.1182/blood-2012-05-430470.
   PubMed Web of Science ®Google Scholar
• Harly C, Peigné C-M, Scotet E. Molecules and mechanisms implicated in the peculiar antigenic activation process of human Vγ9Vδ2 T cells. Front Immunol. 2014;5:657. doi:10.3389/fimmu.2014.00657.
   PubMed Web of Science ®Google Scholar
• Lai D, Wang F, Chen Y, Wang C, Liu S, Lu B, Ge X, Guo L. Human ovarian cancer stem-like cells can be efficiently killed by γδ T lymphocytes. Cancer Immunol Immunother. CII. 2012;61(7):979–989. doi:10.1007/s00262-011-1166-4.
   PubMed Web of Science ®Google Scholar
• Lavoué V, Cabillic F, Toutirais O, Thedrez A, Dessarthe B, de La Pintière CT, Daniel P, Foucher F, Bauville E, Henno S, et al. Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of Vγ9Vδ2 T cells impaired by the prostaglandin E2 immunosuppressive factor: implications for immunotherapy. Int J Cancer. 2012;131(4):E449–462. doi:10.1002/ijc.27353.
   PubMed Web of Science ®Google Scholar
• Jarry U, Chauvin C, Joalland N, Léger A, Minault S, Robard M, Bonneville M, Oliver L, Vallette FM, Vié H, et al. Stereotaxic administrations of allogeneic human Vγ9Vδ2 T cells efficiently control the development of human glioblastoma brain tumors. Oncoimmunology. 2016;5(6):e1168554. doi:10.1080/2162402X.2016.1168554.
   PubMed Web of Science ®Google Scholar
• Fournié -J-J, Sicard H, Poupot M, Bezombes C, Blanc A, Romagné F, Ysebaert L, Laurent G. What lessons can be learned from γδ T cell-based cancer immunotherapy trials? Cell Mol Immunol. 2013;10(1):35–41. doi:10.1038/cmi.2012.39.
   PubMed Web of Science ®Google Scholar
• Helland O, Popa M, Vintermyr OK, Molven A, Gjertsen BT, Bjørge L, McCormack E. First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma. PLoS One. 2014;9(3):e89527. doi:10.1371/journal.pone.0089527.
   PubMed Web of Science ®Google Scholar
• Loubani O, Hoskin DW. Paclitaxel inhibits natural killer cell binding to target cells by down-regulating adhesion molecule expression. Anticancer Res. 2005;25:735–741.
   PubMed Web of Science ®Google Scholar
• Kato Y, Tanaka Y, Hayashi M, Okawa K, Minato N. Involvement of CD166 in the activation of human gamma delta T cells by tumor cells sensitized with nonpeptide antigens. J Immunol Baltim. Md 1950. 2006;177(2):877–884. doi:10.4049/jimmunol.177.2.877.
   PubMed Web of Science ®Google Scholar
• Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Maurer MJ, Perkins SE, AlHilli M, Butler KA, McKinstry S, et al. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20(5):1288–1297. doi:10.1158/1078-0432.CCR-13-2611.
   PubMed Web of Science ®Google Scholar
• Liu JF, Palakurthi S, Zeng Q, Zhou S, Ivanova E, Huang W, Zervantonakis IK, Selfors LM, Shen Y, Pritchard CC, et al. Establishment of patient-derived tumor xenograft models of epithelial ovarian cancer for preclinical evaluation of novel therapeutics. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23(5):1263–1273. doi:10.1158/1078-0432.CCR-16-1237.
   PubMed Web of Science ®Google Scholar
• Cubillos-Ruiz JR, Rutkowski M, Conejo-Garcia JR. Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. Cell Cycle Georget Tex. 2010;9(2):260–268. doi:10.4161/cc.9.2.10430.
   PubMed Web of Science ®Google Scholar
• Dhillon S, Lyseng-Williamson KA. Zoledronic acid : a review of its use in the management of bone metastases of malignancy. Drugs. 2008;68(4):507–534. doi:10.2165/00003495-200868040-00010.
   PubMed Web of Science ®Google Scholar
• Green J, Lipton A. Anticancer properties of zoledronic acid. Cancer Invest. 2010;28(9):944–957. doi:10.3109/07357907.2010.512598.
   PubMed Web of Science ®Google Scholar